Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Recent studies have established that a significant fraction of prostate cancers harbor a signature gene fusion between the 5' region of androgen-regulated TMPRSS2 and an ETS family transcription factor, most commonly ERG. Studies on the molecular mechanisms and functional consequences of this important chromosomal rearrangement are currently limited to the VCaP cell line derived from a vertebral bone metastasis of a hormone-refractory prostate tumor. Here we report on the NCI-H660 cell line, derived from a metastatic site of an extrapulmonary small cell carcinoma arising from the prostate. NCI-H660 harbors TMPRSS2-ERG fusion with a homozygous intronic deletion between TMPRSS2 and ERG. We demonstrate this by real-time quantitative polymerase chain reaction, a two-stage dual-color interphase fluorescence in situ hybridization (FISH) assay testing for TMPRSS2 and ERG break-aparts, and single-nucleotide polymorphism oligonucleotide arrays. The deletion is consistent with the common intronic deletion found on chromosome 21q22.2-3 in human prostate cancer samples. We demonstrate the physical juxtaposition of TMPRSS2 and ERG on the DNA level by fiber FISH. The androgen receptor-negative NCI-H660 cell line expresses ERG in an androgen-independent fashion. This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer.

[1]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[2]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[3]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[4]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[5]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[6]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[7]  M. Rubin,et al.  Prognostic factors in lymph node-positive prostate cancer. , 2005, Urology.

[8]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[9]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[10]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[11]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[12]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[13]  S. P. Fodor,et al.  Large-scale genotyping of complex DNA , 2003, Nature Biotechnology.

[14]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[15]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[16]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[19]  F. Kaye,et al.  Molecular genetic characterization of neuroendocrine lung cancer cell lines. , 1995, Anticancer research.

[20]  S. Naylor,et al.  Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. , 1989, Journal of the National Cancer Institute.

[21]  G. Bepler,et al.  Establishment and identification of small cell lung cancer cell lines having classic and variant features. , 1985, Cancer research.